Stent thrombosis.
Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA. holmes.david@mayo.edu
David R
DR
Holmes
Dean J
DJ
Kereiakes
Scot
S
Garg
Patrick W
PW
Serruys
Gregory J
GJ
Dehmer
Stephen G
SG
Ellis
David O
DO
Williams
Takeshi
T
Kimura
David J
DJ
Moliterno
D015906:Angioplasty, Balloon, Coronary; D054855:Drug-Eluting Stents / Q000009:adverse effects; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control
D010975:Platelet Aggregation Inhibitors